Anges & Vasomune Therapeutics Enter Agreement For AV-001

Reuters
2025.11.25 17:40
Nov 25 (Reuters) - AnGes Inc (4563.T) : * ANGES INC: CO & VASOMUNE THERAPEUTICS ENTER AGREEMENT TO EXPAND RESEARCH INDICATIONS FOR TIE2 RECEPTOR AGONIST PEGEVONGITIDE (AV-001) Source text: Further company coverage: (4563.T)
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2025 Longbridge｜Disclaimer